The gap no label tells you about

Every morning, millions of people line up their capsules alongside breakfast — magnesium, vitamin D, a curcumin complex, perhaps a CoQ10 — and swallow them with the quiet confidence that a well-chosen ingredient is a delivered ingredient. The dose is on the label. The research is cited on the box. Job done.

Except the story does not end at the throat.

Between swallowing a supplement and that compound actually reaching your cells lies a gauntlet of digestive chemistry, enzymatic breakdown, and metabolic filtering that the label says nothing about. The fraction of an ingested substance that makes it into systemic circulation — its bioavailability — is almost always less than the stated dose, and for some compounds it is dramatically so. This is not a niche caveat buried in academic literature; it is a foundational reality of pharmacology that applies to virtually every orally ingested compound, however premium its source.

Understanding why that gap exists — and what, if anything, can be done to close it — is what the rest of this article is for.

What bioavailability actually means

Think of a message sent across a city that must pass through two busy sorting offices before it reaches its destination. At each stop, clerks pull out pages, redraft passages, and discard anything they flag as redundant. By the time the message arrives, it may carry only a fraction of its original content — and the recipient has no way of knowing what was edited out.

That, in essence, is what happens to most oral supplements before they reach your cells. Bioavailability — the percentage of an ingested compound that enters systemic circulation in an active form — is the measure of how much actually gets through. Intravenous delivery sets the ceiling at 100%, because nothing is lost in transit. The oral route rarely comes close.

The mechanism responsible is called the first-pass effect. When a compound is swallowed, it is absorbed through the gut wall and routed directly to the liver before it reaches general circulation. Both the gut lining and the liver contain enzymes whose job is to process — and often deactivate — incoming substances. A meaningful portion of the original dose can be metabolised at this stage alone, regardless of how much the label says you have taken.

Route of administration is therefore not a logistical detail; it is a pharmacological variable that determines effective dose. The same compound, delivered differently, can reach the bloodstream at very different concentrations.

Individual biology complicates this further. Enzyme genetics, gut microbiome composition, and day-to-day digestive health all vary considerably from person to person — meaning two people taking identical capsules may absorb strikingly different amounts.

Promising in the lab, limited in the gut

Curcumin makes an instructive case. The compound found in turmeric has been studied for its antioxidant and anti-inflammatory properties, and in laboratory conditions it performs convincingly. In the body, however, its oral bioavailability is characterised as very poor — meaning that however much is printed on the packet, only a small fraction typically reaches systemic circulation in an active form, resulting in limited real-world efficacy at standard doses.

This is not a problem unique to curcumin. The same pattern — biologically active under laboratory conditions, disappointing when swallowed — recurs across a wide range of compounds: fat-soluble vitamins, polyphenols, and coenzyme cofactors among them. The issue is not ingredient quality. A high-purity extract, rigorously sourced, still faces the same gauntlet of enzymatic breakdown, gut-wall filtering, and first-pass metabolism as a cheaper alternative. The gut is a filter by design, not a pipe.

What this means practically is that compound selection and delivery method cannot be treated as separate decisions. A compound chosen for its biological activity may underperform not because it is the wrong ingredient but because the route of delivery is mismatched to it. The question "what should I take?" is incomplete without asking how it will actually reach the cells it is meant to serve.

Professor Paul Lee's Chemistry layer and the 'too much, too blind' problem

The supplement industry's answer to absorption uncertainty has largely been more: more products, more formulations, more daily servings. In Practical Regeneration (FCM Publishing, 2026), Professor Paul Lee — orthopaedic surgeon, medical engineer, and author of Regeneration by Design — names the result precisely: 'too much, too blind.' More compounds swallowed with diminishing attention to whether any of them are reaching their cellular target.

Lee organises health optimisation around four interdependent pillars: Physics, Chemistry, Biology, and Time. Chemistry covers the body's internal environment — nutrition, hormones, inflammation, and the inputs that signal repair. Oral supplementation sits squarely within it, which means the delivery gap is not a niche technical concern but a structural failure at the Chemistry layer — one that quietly undermines the others. Poor absorption produces blunted biological signals; blunted signals mean slower repair; slower repair is a Time problem as much as a Chemistry one.

Within Chemistry, Lee distinguishes between the foundations — balanced nutrition, movement, stress management — and what he calls the 'Formula 1' layer. The foundations keep the engine running; precision delivery is where performance, resilience, and recovery are pushed further. His position on conventional supplementation follows from this: 'most oral supplements never reach full effectiveness due to digestive breakdown and absorption limits,' and therefore 'delivery matters as much as content.'

That is not a commercial proposition; it is a pharmacological one — and it maps directly onto the mechanism the preceding sections describe. Lee's contribution is the framing that makes it actionable: delivery is a Chemistry decision, and treating it as an afterthought leaves the whole system working below its capacity.

Closing the gap: what better delivery actually looks like

Three distinct tiers sit between a standard capsule and a cell that actually receives what was intended.

Liposomal formulations wrap active compounds in lipid-bilayer vesicles — structures that mimic cell membranes and can partially shield contents from enzymatic breakdown in the upper gut. The structural rationale is sound: encapsulation creates a more favourable passage through a hostile digestive environment. Specific clinical outcome data comparing liposomal to conventional oral supplements remains limited, so the honest position is that they represent a meaningful engineering improvement rather than a proven equivalent to higher-bioavailability routes.

Nanoparticle delivery systems extend the same engineering logic — targeted delivery, controlled release, reduced dosing frequency — but remain a research-stage technology rather than a mainstream supplementation option.

Intravenous nutrient delivery sidesteps the gastrointestinal pipeline entirely. There is no gut wall to cross, no first-pass metabolism to trim the dose, no enzymatic breakdown en route. Bioavailability, by definition, is complete at the point of entry into systemic circulation. This is the principle behind the IV nutrient protocol Professor Paul Lee has refined across two decades of clinical practice — a pharmaceutical-grade formulation, administered by a trained clinician in approximately twenty minutes, with outcomes logged longitudinally for pattern review. Even so, how much any IV protocol measurably moves the dial for a given individual depends on their starting point and on whether the other pillars — Physics, Biology, and Time — are working alongside it. The delivery mechanism is not in question; the degree of individual benefit remains, honestly, a variable.

In Practical Regeneration, Lee is direct: the foundations come first. IV delivery is the precision adjunct at the 'Formula 1' layer, not a replacement for the engine beneath it.

What to actually do this week

Before buying another supplement, ask one question: does this compound actually have a reliable route from gut to cell?

That question reframes what a practical audit looks like.

• Identify the problem compounds. Fat-soluble vitamins, polyphenols, and coenzyme cofactors are the most common absorption casualties. If something on your shelf falls into those categories, check whether an enhanced-delivery format — liposomal formulations being the most accessible — exists for it.
• Support the pipeline itself. Gut health governs the oral absorption ceiling; attending to Biology is part of the Chemistry equation, not separate from it.
• Consider IV delivery if you are already optimising at the margins — not as a starting point, but as the precision adjunct Professor Paul Lee describes in Practical Regeneration: the 'Formula 1' layer that sits above solid foundations, not in place of them.

The Regeneration by Design principle at work here is specific rather than general: delivery precision within Chemistry amplifies what Biology can receive, which compounds what Physics and Time build on. The pillars multiply — they do not queue.

Spending more on the same poorly-absorbed oral route is not optimisation. The delivery question deserves a place on the label. It just isn't there yet.

This article reflects general wellness principles, not medical advice. For individual health concerns or significant changes to your supplement regimen, consult a qualified healthcare professional.

1. [1] Bioavailability. https://en.wikipedia.org/?curid=769021 https://en.wikipedia.org/?curid=769021
2. [2] EF-24 (curcumin analogue). https://en.wikipedia.org/?curid=66177541 https://en.wikipedia.org/?curid=66177541
3. [3] Enteral administration. https://en.wikipedia.org/?curid=5565398 https://en.wikipedia.org/?curid=5565398